Hepatotoxicity of Commonly Used Drugs: Nonsteroidal Anti-Inflammatory Drugs, Antihypertensives, Antidiabetic Agents, Anticonvulsants, Lipid-Lowering Agents, Psychotropic Drugs

Shivakumar Chitturi; Jacob George

doi:10.1055/s-2002-30102

Seminars in Liver Disease, Table of Contents

Semin Liver Dis 2002; 22(2): 169-184
DOI: 10.1055/s-2002-30102

Hepatotoxicity of Commonly Used Drugs: Nonsteroidal Anti-Inflammatory Drugs, Antihypertensives, Antidiabetic Agents, Anticonvulsants, Lipid-Lowering Agents, Psychotropic Drugs

Shivakumar Chitturi, Jacob George

Storr Liver Unit, Westmead Millennium Institute, University of Sydney at Westmead Hospital, Westmead, NSW, Australia

Abstract

ABSTRACT

Hepatotoxic adverse drug reactions have contributed to the decline of many promising therapies, even among mainstream medication classes (bromfenac and troglitazone are recent examples). The spectrum of nonsteroidal anti-inflammatory drug-related liver toxicity continues to expand, with reports in children, interactive toxicity in persons with hepatitis C, and recognition of the toxicity of both the preferential and selective cyclooxygenase-2 inhibitors. Of the antihypertensive agents, methyldopa is now rarely prescribed and adverse effects are reported infrequently, whereas cases of liver injury associated with the angiotensin receptor and converting enzyme inhibitors are increasingly reported. Of the antidiabetic agents, acarbose, gliclazide, metformin, and human insulin have been implicated in causing liver injury. To date, the newer thiazolidinediones do not appear to share the hepatotoxic potential of troglitazone, although a few reports of acute hepatitis have accrued. Although liver injury has been associated with the ``statins,'' the frequency of such toxicity is lower than that of the background population and the value of biochemical monitoring remains unproved. Newer concepts in anticonvulsant hepatotoxicity have been the recognition of the reactive metabolite syndrome, delineation of the risk factors for valproic acid toxicity, the potential role of carnitine in preventing valproic acid hepatotoxicity, and the toxicity of second-line antiepileptic drugs. Liver injury associated with newer psychotropic agents, particularly the selective serotonin reuptake inhibitors, is also discussed. The focus of the review is the hepatotoxicity of commonly used drugs with particular reference to recent and novel reports of toxicity. Well-known causes of liver injury such as chlorpromazine, phenytoin, and methyldopa are not discussed.

KEYWORDS

Hepatotoxicity - drug-induced liver disease - liver injury - cholestasis - fulminant hepatic failure - antihypertensive drugs - antidiabetic agents - nonsteroidal anti-inflammatory drugs - psychotropic agents

Full Text

References

REFERENCES

1 Friis H, Andreasen P B. Drug-induced hepatic injury: an analysis of 1100 case reports to the Danish Committee on Adverse Drug Reactions between 1978 and 1987. J Intern Med . 1992; 232 133-138
2 Fontana R J, McCashland T M, Benner K G. Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. The Acute Liver Failure Study Group. Liver Transpl Surg . 1999; 5 480-484
3 Garcia Rodriguez A L, Williams R, Derby L E. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med . 1994; 154 311-316
4 Garcia Rodriguez A L, Perez Gutthann S, Walker A M, Lueck L. The role of non-steroidal anti-inflammatory drugs in acute liver injury. BMJ . 1992; 305 865-868
5 Hernandez-Diaz S, Garcia-Rodriguez L A. Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med . 2001; 110(Suppl 3A) 20S-27S
6 Laffi G, La Villa G, Pinzani M. Arachidonic acid derivatives and renal function in liver cirrhosis. Semin Nephrol . 1997; 17 530-548
7 De Ledinghen V, Heresbach D, Fourdan O. Anti-inflammatory drugs and variceal bleeding: a case-control study. Gut . 1999; 44 270-273
8 Autret-Leca E, Jonville-Bera A P, Llau M E. Incidence of Reye's syndrome in France: a hospital-based survey. J Clin Epidemiol . 2001; 54 857-862
9 Belay E D, Bresee J S, Holman R C. Reye's syndrome in the United States from 1981 through 1997. N Engl J Med . 1999; 340 1377-1382
10 Buttar N S, Wang K K. The ``aspirin'' of the new millennium: cyclooxygenase-2 inhibitors. Mayo Clin Proc . 2000; 75 1027-1038
11 Maddrey W C, Maurath C J, Verburg K M, Geis G S. The hepatic safety of and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib. Am J Ther . 2000; 7 153-158
12 O'Beirne J P, Cairns S R. Drug points: cholestatic hepatitis in association with celecoxib (letter). BMJ . 2001; 323 23
13 Galan M V, Gordon S C, Silverman A L. Celecoxib-induced cholestatic hepatitis (letter). Ann Intern Med . 2001; 134 254
14 Carrillo-Jimenez R, Nurnberger M. Celecoxib-induced acute pancreatitis and hepatitis. Arch Intern Med . 2000; 170 553-554
15 Jones D B. COX-2 inhibitors (letter). Med J Aust . 2001; 174 368
16 Nachimuthu S, Volfinzon L, Gopal L. Acute hepatocellular and cholestatic injury in a patient taking celecoxib. Postgrad Med J . 2001; 77 548-550
17 Knowles S, Shapiro L, Shear N H. Should celecoxib be contraindicated in patients who are allergic to sulfonamides?. <~>Revisiting the meaning of `sulfa' allergy. Drug Saf . 2001; 24 239-247
18 Tilles S A. Practical issues in the management of hypersensitivity reactions: sulfonamides. South Med J . 2001; 94 817-824
19 Van Steenbergen W, Peeters P, De Bondt J. Nimesulide-induced acute hepatitis: evidence from six cases. J Hepatol . 1998; 29 135-141
20 Schattner A, Sokolovskaya N, Cohen J. Fatal hepatitis and renal failure during treatment with nimesulide. J Intern Med . 2000; 247 153-155
21 Andrade R J, Lucena M I, Fernandez M C, Gonzalez M. Fatal hepatitis associated with nimesulide. J Hepatol . 2000; 32 174
22 Weiss P, Mouallem M, Bruck R. Nimesulide-induced hepatitis and acute liver failure. Isr Med Assoc J . 1999; 1 89-91
23 McCormick P A, Kennedy F, Curry M, Traynor O. COX-2 inhibitor and fulminant hepatic failure (letter). Lancet . 1999; 353 40-41
24 Staerkel P, Horsmans Y. Meloxicam-induced liver toxicity. Acta Gastroenterol Belg . 1999; 62 255-256
25 Mabee C L, Mabee S W, Baker P B. Fulminant hepatic failure associated with etodolac use. Am J Gastroenterol . 1995; 90 659-661
26 Stempel D A, Miller 3rd J J. Lymphopenia and hepatic toxicity with ibuprofen. J Pediatr . 1977; 90 657-658
27 Alam I, Ferrell L D, Bass N M. Vanishing bile duct syndrome temporally associated with ibuprofen use. Am J Gastroenterol . 1996; 91 1626-1630
28 Laurent S, Rahier J, Geubel A P. Subfulminant hepatitis requiring liver transplantation following ibuprofen overdose. Liver . 2000; 20 93-94
29 Srivastava M, Perez-Atayde A, Jonas M M. Drug-associated acute-onset vanishing bile duct and Stevens-Johnson syndromes in a child. Gastroenterology . 1998; 115 743-746
30 Sternlieb P, Robinson R M. Stevens-Johnson syndrome plus toxic hepatitis due to ibuprofen. NY State J Med . 1978; 78 1239-1243
31 Riley 3rd R T, Smith J P. Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: a case series. Am J Gastroenterol . 1998; 93 1563-1565
32 Guldenschuh I, Hurlimann R, Muller A. Relationship between APC genotype, polyp distribution, and oral sulindac treatment in the colon and rectum of patients with familial adenomatous polyposis. Dis Colon Rectum . 2001; 44 1090-1097
33 Tarazi E M, Harter J G, Zimmerman H J. Sulindac-associated hepatic injury: analysis of 91 cases reported to the Food and Drug Administration. Gastroenterology . 1993; 104 569-574
34 Lerche A, Vyberg M, Kirkegaard E. Acute cholangitis and pancreatitis associated with sulindac (Clinoril). Histopathology . 1987; 11 647-653
35 Bolder U, Trang N V, Hagey L R. Sulindac is excreted into bile by a canalicular bile salt pump and undergoes a cholehepatic circulation in rats. Gastroenterology . 1999; 117 962-971
36 Helfgott S M, Sandberg-Cook J, Zakim D, Nestler J. Diclofenac-associated hepatotoxicity. JAMA . 1990; 264 2660-2662
37 Iveson T J, Ryley N G, Kelly P MA. Diclofenac associated hepatitis. J Hepatol . 1990; 10 85-89
38 Breen E G, McNicholl J, Cosgrove E. Fatal hepatitis associated with diclofenac. Gut . 1986; 27 1390-1393
39 Banks A T, Zimmerman H J, Ishak K G, Harter J G. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology . 1995; 22 820-827
40 Scully L J, Clarke D, Barr R J. Diclofenac induced hepatitis. 3 cases with features of autoimmune chronic active hepatitis. Dig Dis Sci . 1993; 38 744-751
41 Greaves R R, Agarwal A, Patch D. Inadvertent diclofenac rechallenge from generic and non-generic prescribing, leading to liver transplantation for fulminant liver failure. Eur J Gastroenterol Hepatol . 2001; 13 71-73
42 Aithal G P, Day C P, Leathart J B, Daly A K. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics . 2000; 10 511-518
43 Bort R, Ponsoda X, Jover R. Diclofenac toxicity to hepatocytes: a role for drug metabolism in cell toxicity. J Pharmacol Exp Ther . 1999; 288 65-72
44 Zimmerman H J. Effects of aspirin and acetaminophen on the liver. Arch Intern Med . 1981; 141 333-342
45 Cappell M S, Kozicky O, Competiello L S. Indomethacin-associated cholestasis. J Clin Gastroenterol . 1988; 10 445-447
46 Victorino R M, Silveira J C, Baptista A, de Moura C M. Jaundice associated with naproxen. Postgrad Med J . 1980; 56 368-370
47 Kethu S R, Rukkannagari S, Lansford C L. Oxaprozin-induced symptomatic hepatotoxicity. Ann Pharmacother . 1999; 33 942-944
48 Purdum 3rd P P, Shelden S L, Boyd J W, Shiffman M L. Oxaprozin-induced fulminant hepatitis. Ann Pharmacother . 1994; 28 1159-1161
49 Paterson D, Kerlin P, Walker N. Piroxicam induced submassive necrosis of the liver. Gut . 1992; 33 1436-1438
50 Sherman K E, Jones C. Hepatotoxicity associated with piroxicam use. Gastroenterology . 1992; 103 354-355
51 Katsinelos P, Katsos I, Patsiaoura K. Tenoxicam-associated hepatic injury: a case report and review. Eur J Gastroenterol Hepatol . 1997; 9 403-406
52 Garcia-Rodriguez L A, Cattaruzzi C, Grazia Troncon M. Acute liver injury and droxicam use in the region of Friuli-Venezia Giulia. Br J Clin Pharmacol . 1995; 40 104-105
53 Cohen S, Cannon G W, Schiff M. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of leflunomide in the treatment of rheumatoid arthritis trial investigator group. Arthritis Rheum . 2001; 44 1984-1992
54 Weinblatt M E, Dixon J A, Falchuk K R. Serious liver disease in a patient receiving methotrexate and leflunomide. Arthritis Rheum . 2000; 43 2609-2611
55 Targan S R, Hanauer S B, van Deventer J H S. Crohn's Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor-alpha for Crohn's disease. N Engl J Med . 1997; 337 1029-1035
56 Hanauer S B. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther . 1999; 13(Suppl 4) 16-22
57 Menghini V V, Arora A S. Infliximab-associated reversible cholestatic liver disease. Mayo Clin Proc . 2001; 76 84-86
58 Saleem G, Li S C, MacPherson B R. Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy. Arthritis Rheum . 2001; 44 1966-1968
59 Reinus J F, Persky S, Burkiewicz J S. Severe liver injury after treatment with the leukotriene receptor antagonist zafirlukast. Ann Intern Med . 2000; 133 964-968
60 Torres M, Reddy K R. Severe liver injury (letter). Ann Intern Med . 2001; 135 550
61 Moles J R, Primo J, Fernandez J M, Hinojosa J E. Acute hepatocellular injury associated with zafirlukast (letter). J Hepatol . 2001; 35 541-542
62 Actis G C, Morgando A, Lagget M. Zafirlukast-related hepatitis: report of a further case (letter). J Hepatol . 2001; 35 539-541
63 Maddrey W C, Boitnott J K. Severe hepatitis from methyldopa. Gastroenterology . 1975; 68 351-360
64 Tanner L A, Bosco L A, Zimmerman H J. Hepatic injury after acebutalol. Ann Intern Med . 1989; 111 533-534
65 Larrey D, Henrion J, Heller F. Metoprolol-induced hepatitis: rechallenge and drug oxidation phenotyping. Ann Intern Med . 1988; 108 67-68
66 Schwartz M S. Atenolol-associated cholestasis. Am J Gastroenterol . 1989; 184 1084-1086
67 Yusuf S W, Mishra R M. Hepatic dysfunction associated with atenolol. Lancet . 1995; 346 192
68 Clark J, Zimmerman H J, Tanner L. Labetalol hepatotoxicity. Ann Intern Med . 1990; 113 210-213
69 Kumar K L, Colley C A. Verapamil-induced hepatotoxicity. West J Med . 1994; 160 485-486
70 Toft E, Vyberg M, Therkelsen K. Diltiazem-induced granulomatous hepatitis. Histopathology . 1991; 18 474-475
71 Babany G, Uzzan F, Larrey D. Alcoholic-like liver lesions induced by nifedipine. Hepatology . 1989; 9 252-255
72 Nunes A C, Amaro P, Mac as F. Fosinopril-induced prolonged cholestatic jaundice and pruritus: first case report. Eur J Gastroenterol Hepatol . 2001; 13 279-282
73 Rahmat J, Gelfand R L, Gelfand M. Captopril-associated cholestatic jaundice. Ann Intern Med . 1985; 102 56-58
74 Rosellini S R, Costa P L, Gaudio M. Hepatic injury related to enalapril. Gastroenterology . 1989; 97 810
75 Todd P, Levison D, Farthing M JG. Enalapril-related cholestatic jaundice. J R Soc Med . 1990; 83 271-272
76 Hagley M T, Hulisz D T, Burns C M. Hepatotoxicity associated with angiotensin-converting enzyme inhibitors. Ann Pharmacother . 1993; 27 228-231
77 Jeserich M, Ihling C, Allgaier H P. Acute liver failure due to enalapril. Herz . 2000; 25 689-693
78 Larrey D, Babany G, Bernuau J. Fulminant hepatitis after lisinopril administration. Gastroenterology . 1990; 99 1832-1833
79 Hagley M T, Benak R L, Hulisz D T. Suspected cross-reactivity of enalapril- and captopril-induced hepatotoxicity. Ann Pharmacother . 1992; 26 780-781
80 Hariraj R, Stoner E, Jader S, Preston D M. Drug points: prolonged cholestasis associated with irbesartan. BMJ . 2000; 321 547
81 See S, Stirling A L. Candesartan cilexetil: an angiotensin II-receptor blocker. Am J Health Syst Pharm . 2000; 57 739-746
82 Vallejo I, Garcia Morillo S, Pamies E. Acute hepatitis induced by candesartan. Med Clin (Barc) . 2000; 115 719
83 Gonzalez-Jimenez D, Varela J M, Calderon E. Candesartan and acute liver injury. Eur J Clin Pharmacol . 2000; 56 769-770
84 Andrade R J, Lucena M I, Santalla F. Hepatic injury associated with losartan. Ann Pharmacother. 1998; 32 1371
85 Gonzalez-Abraldes J, Albillos A, Banares R. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology . 2001; 121 382-388
86 Schneider A W, Kalk J F, Klein C P. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology . 1999; 29 334-339
87 Nygaard B, Strandgaard S. Marked hepatotoxicity associated with losartan treatment. Blood Press . 1996; 5 190-191
88 Thai K E, Sinclair R D. Spironolactone-induced hepatitis. Australas J Dermatol . 2001; 42 180-182
89 Renkes P, Gaucher P, Trechot P. Spironolactone and hepatic toxicity. JAMA . 1995; 273 376-377
90 Shuck J, Shen S, Owensby L. Spironolactone hepatitis in primary hyperaldosteronism. Ann Intern Med . 1981; 95 708-710
91 Cetin M, Demirci D, Unal A. Frequency of flutamide induced hepatotoxicity in patients with prostate carcinoma. Hum Exp Toxicol . 1999; 18 137-140
92 Andrade R J, Lucena M I, Fernandez M C. Fulminant liver failure associated with flutamide therapy for hirsutism (letter). Lancet . 1999; 33 983
93 Jick S S, Stender M, Myers M W. Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents. Diabetes Care . 2000; 22 2067-2071
94 Schneider H L, Hornbach K D, Kniaz J L, Efrusy M E. Chlorpropamide hepatotoxicity: report of a case and review of the literature. Am J Gastroenterol . 1984; 79 721-724
95 Goodman R C, Dean P J, Radparvar A, Kitabchi A E. Glyburide-induced hepatitis. Ann Intern Med . 1987; 106 837-839
96 Wongpaitoon V, Russell R F, Mills P R, Patrick R S. Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy. Postgrad Med . 1981; 57 244-246
97 Saw D, Pitman E, Maung M. Granulomatous hepatitis associated with glyburide. Dig Dis Sci . 1996; 41 322-325
98 Gregory D H, Zaki G F, Sarosi G A, Carey Jr B J. Chronic cholestasis following prolonged tolbutamide administration. Arch Pathol . 1967; 84 194
99 Van Thiel H D, de Belle R, Mellow M. Tolazamide hepatotoxicity. Gastroenterology . 1974; 67 506-510
100 Nakao N L, Gelb A M, Stenger R, Sitgel J H. A case of chronic liver disease due to tolazamide. Gastroenterology . 1985; 89 192-195
101 Chitturi S, Le V, Kench J. Gliclazide-induced acute hepatitis with hypersensitivity features (in press). Dig Dis Sci.
102 Dourakis S P, Tzemanakis E, Sinani C. Gliclazide-induced acute hepatitis. Eur J Gastroenterol Hepatol . 2000; 12 119-121
103 Sitruk V, Mohib S, Grando-Lemaire V. Acute cholestatic hepatitis induced by glimepiride. Gastroenterol Clin Biol . 2000; 24 1233-1234
104 Clarke B F, Campbell J W, Ewing D J. Generalized hypersensitivity reaction and visceral arteritis with fatal outcome during glibenclamide therapy. Diabetes . 1974; 23 739-742
105 Van Basten P J, Van Hoek B, Zeijen R, Stockbrugger R. Glyburide-induced cholestatic hepatitis and liver failure. Case report and review of the literature. Neth J Med . 1992; 40 305-307
106 Babich M M, Pike I, Shiffman M L. Metformin-induced acute hepatitis. Am J Med . 1998; 104 490-492
107 Desilets D J, Shorr A F, Moran K A, Holtzmuller K C. Cholestatic jaundice associated with the use of metformin. Am J Gastroenterol . 2001; 96 2257-2258
108 Harrigan R A, Nathan M S, Beattie P. Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment. Ann Emerg Med . 2001; 38 68-78
109 Andrade R J, Lucena M, Vega J L. Acarbose-associated hepatotoxicity (letter). Diabetes Care . 1998; 21 2029-2030
110 Carrascosa M, Pascual F, Aresti S. Acarbose-induced acute severe hepatotoxicity (letter). Lancet . 1997; 349 698-699
111 Fujimoto Y, Ohhira M, Miyokawa N. Acarbose-induced hepatic injury (letter). Lancet . 1998; 351 340
112 Masumoto T, Ishikawa M, Yamauchi Y. Drug-induced hepatitis with severe cholestasis due to voglibose. Int Hepatol Commun . 1996; 5 289-296
113 Scott L J, Spencer C M. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. Drugs . 2000; 59 512-549
114 Vella A, de Groen C P, Dinneen S F. Fatal hepatotoxicity associated with troglitazone (letter). Ann Intern Med . 1998; 129 1080
115 Murphy E J, Davern T J, Shakil O. Troglitazone-induced fulminant hepatic failure. Dig Dis Sci . 2000; 45 549-553
116 Schiano T, Dolehide K, Hart J, Baker A L. Severe but reversible hepatitis induced by troglitazone. Dig Dis Sci . 2000; 45 1039-1042
117 Gitlin N, Julie N L, Spurr C L. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med . 1998; 129 36-38
118 Neuschwander-Tetri B A, Isley W L, Oki J C. Troglitazone-induced hepatic failure leading to liver transplantation. Ann Intern Med . 1998; 129 38-41
119 Malik A H, Prasad P, Saboorian M H. Hepatic injury due to troglitazone. Dig Dis Sci . 2000; 45 210-214
120 Bloomgarden Z T. American Diabetes Association 60th Scientific Sessions, 2000; thiazolidinediones, obesity, and related topics. Diabetes Care . 2001; 24 162-166
121 Kohlroser J, Mathai J, Reichheld J. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol . 2000; 95 272-276
122 Watkins P B, Whitcomb R W. Hepatic dysfunction associated with troglitazone (letter). N Engl J Med . 1998; 338 916-917
123 Caldwell S H, Hespenheide E E, von Borstel W R. Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin. Dig Dis Sci . 2001; 46 376-378
124 Bell D SH, Ovalle F. Late-onset troglitazone-induced hepatic dysfunction (letter). Diabetes Care . 2000; 23 128-129
125 Iwase M, Yamaguchi M, Yoshinari M. A Japanese case of liver dysfunction after 19 months of troglitazone treatment. Diabetes Care . 1999; 22 1382-1384
126 Jagannath S, Rai R. Rapid-onset subfulminant liver failure associated with troglitazone. Ann Intern Med . 2000; 132 677
127 Menon K VN, Angulo P, Lindor K D. Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus. Am J Gastroenterol . 2001; 96 1631-1634
128 Caldwell S H. Efficacy and safety of troglitazone for lipodystrophy syndromes. Ann Intern Med . 2001; 134 1008
129 Funk C, Ponelle C, Scheuermann G, Pantze M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol . 2001; 59 627-635
130 Shibuya A, Watanabe M, Yoshikuni F. An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care . 1998; 21 2140-2143
131 Rubin C J, Schneider R L. Pioglitazone liver enzyme profile is similar to placebo in U.S. controlled clinical trials. Diabetes . 2000; 49(Suppl 1) A123
132 Lebovitz H E, Salzman A. Rosiglitazone liver safety update. Diabetes . 2000; 49(Suppl 1) A39
133 Forman L M, Simmons D A, Diamond R H. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med . 2000; 132 118-121
134 Al-Salman J, Arjomand H, Kemp D G, Mittal M. Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann Intern Med . 2000; 132 121-124
135 Freid J, Everitt D, Boscia J. Rosiglitazone and hepatic failure (letter). Ann Intern Med . 2000; 132 164
136 Maeda K. Hepatocellular injury in a patient receiving pioglitazone (letter). Ann Intern Med . 2001; 135 306
137 Hachey D M, O'Neil M P, Force R W. Isolated elevation of alkaline phosphatase level associated with rosiglitazone (letter). Ann Intern Med . 2000; 133 752
138 Lenhard M J, Funk W B. Failure to develop hepatic injury from rosiglitazone in a patient with a history of troglitazone-induced hepatitis. Diabetes Care . 2001; 24 168-169
139 Tawata M, Ikeda M, Kodama Y. A type 2 diabetic patient with liver dysfunction due to human insulin. Diabetes Res Clin Pract . 2000; 49 17-21
140 Tolman K G. Defining patient risks from expanded preventive therapies. Am J Cardiol . 2000; 85 15E-19E
141 Farmer J A, Torre-Amione G. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf . 2000; 23 197-213
142 Ballare M, Xampanini M, Airoldi G. Hepatotoxicity of hydroxy-methylglutaryl-coenzyme A reductase inhibitors. Minerva Gastroenterol Dietol . 1992; 38 41-44
143 Nakad A, Bataille L, Hamoir V. Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin. Lancet . 1999; 353 1763-1764
144 Wierzbicki A S, Crook M A. Cholestatic liver dysfunction. Lancet . 1999; 354 954
145 Grimbert S, Pessayre D, Degott C, Benhamou J P. Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin. Dig Dis Sci . 1994; 39 2032-2033
146 Hartleb M, Rymarczyk G, Januszewski K. Acute cholestatic hepatitis associated with pravastatin. Am J Gastroenterol . 1999; 94 1388-1390
147 Huchzermeyer H, Munzenmaier R. Lovastatin-induced acute cholestatic hepatitis. Dtsch Med Wochenschr . 1995; 120 252-256
148 Gascon A, Zabala S, Iglesias E. Acute cholestasis during long-term treatment with fluvastatin in a nephrotic patient. Nephrol Dial Transplant . 1999; 14 1038
149 Athyros V G, Papageorgiou A A, Hatzikonstandinou H A. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol . 1997; 80 608-613
150 Punthakee Z, Scully L J, Guindi M M, Ooi T C. Liver fibrosis attributed to lipid lowering medications: two cases. J Intern Med . 2001; 250 249-254
151 Ganne-Carrie N, de Leusse A, Guettier C. Autoimmune hepatitis induced by fibrates. Gastroenterol Clin Biol . 1998; 22 525-529
152 Lepicard A, Mallat A, Zafrani E S, Dhumeaux D. Chronic lesion of the interlobular bile ducts induced by fenofibrate. Gastroenterol Clin Biol . 1994; 18 1033-1035
153 Chatrenet P, Regimbeau C, Ramain J P. Chronic active cirrhogenic hepatitis induced by fenofibrate. Gastroenterol Clin Biol . 1993; 17 612-613
154 Lelouch S, Pelletier G, Sinico M. Fenofibrate-induced acute hepatitis with pseudo-cholangitis. Gastroenterol Clin Biol . 1992; 16 597-599
155 Abookire S A, Karson A S, Fiskio J, Bates D W. Use and monitoring of ``statin'' lipid-lowering drugs compared with guidelines. Arch Intern Med . 2001; 161 53-58
156 Vittorio C, Muglia J. Anticonvulsant hypersensitivity syndrome. Arch Intern Med . 1995; 155 2285-2290
157 Knowles S R, Uetrecht J, Shear N H. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet . 2000; 356 1587-1591
158 Schlienger R, Knowles S, Shear N. Lamotrigine-associated anticonvulsant hypersensitivity syndrome. Neurology . 1998; 51 1172-1175
159 Bryant 3rd E A, Dreifuss F E. Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology . 1996; 46 465-469
160 Krahenbuhl S, Brandner S, Kleinle S. Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. Liver . 2000; 20 346-348
161 Konig S A, Schenk M, Sick C. Fatal liver failure associated with valproate therapy in a patient with Friedreich's disease: review of valproate hepatotoxicity in adults. Epilepsia . 1999; 40 1036-1040
162 Schwabe M J, Dobyns W B, Burke B, Armstrong D L. Valproate-induced liver failure in one of two siblings with Alpers disease. Pediatr Neurol . 1997; 16 337-343
163 Njolstad P R, Skjeldal O H, Agsteribbe E. Medium chain acyl-CoA dehydrogenase deficiency and fatal valproate toxicity. Pediatr Neurol . 1997; 16 160-162
164 Raskind J Y, El-Chaar G M. The role of carnitine supplementation during valproic acid therapy. Ann Pharmacother . 2000; 34 630-638
165 Coulter D L. Carnitine, valproate, and toxicity. J Child Neurol . 1991; 6 7-14
166 Bohan T P, Helton E, McDonald I. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology . 2001; 56 1405-1409
167 Kayihan N, Nennesomo I, Ericzon B G, Nemeth A. Fatal deterioration of neurological disease after orthotopic liver transplantation for valproic acid-induced liver damage. Pediatr Transplant . 2000; 4 211-214
168 Thomson M A, Lynch S, Strong R. Orthotopic liver transplantation with poor neurologic outcome in valproate-associated liver failure: a need for critical risk-benefit appraisal in the use of valproate. Transplant Proc . 2000; 32 200-203
169 Makin A J, Fitt S, Williams R, Duncan J S. Fulminant hepatic failure induced by lamotrigine. BMJ . 1995; 311 292
170 Sauve G, Bresson-Hadni S, Prost P. Acute hepatitis after lamotrigine administration. Dig Dis Sci . 2000; 45 1874-1877
171 Arnon R, DeVivo D, Defelice A R, Kazlow P G. Acute hepatic failure in a child treated with lamotrigine. Pediatr Neurol . 1998; 18 251-252
172 Fayad M, Choueiri R, Mikati M. Potential hepatotoxicity of lamotrigine. Pediatr Neurol . 2000; 22 49-52
173 Bjoro K, Gjerstad L, Bentdal O. Topiramate and fulminant liver failure. Lancet . 1998; 352 1119
174 Doan R J, Clendenning M. Topiramate and hepatotoxicity. Can J Psychiatry . 2000; 45 937-938
175 O'Neil M G, Perdun C S, Wilson M B. Felbamate-associated fatal acute hepatic necrosis. Neurology . 1996; 46 1457-1459
176 Pellock J M. Felbamate. Epilepsia . 1999; 40(Suppl 5) S57-S62
177 Thompson C D, Kinter M T, Macdonald T L. Synthesis and in vitro reactivity of 3-carbamoyl-2-phenylpropionaldehyde and 2-phenylpropenal: putative reactive metabolites of felbamate. Chem Res Toxicol . 1996; 9 1225-1229
178 Ishak K G, Irey N S. Hepatic injury associated with the phenothiazines. Clinicopathologic and follow-up study of 36 patients. Arch Pathol . 1972; 93 283-304
179 Dincsoy H P, Saelinger D A. Haloperidol-induced chronic cholestatic liver disease. Gastroenterology . 1982; 83 694-700
180 Lok A S, Ng I O. Prochlorperazine-induced chronic cholestasis. J Hepatol . 1988; 6 369-373
181 Villari D, Rubino F, Corica F. Bile ductopenia following therapy with sulpiride. Virchows Arch . 1995; 427 223-226
182 Macfarlane B, Davies S, Mannan K. Fatal acute fulminant liver failure due to clozapine: a case report and review of clozapine-induced hepatotoxicity. Gastroenterology . 1997; 112 1707-1709
183 Krebs S, Dormann H, Muth-Selbach U. Risperidone-induced cholestatic hepatitis. Eur J Gastroenterol Hepatol . 2001; 13 67-69
184 Cadario B. Olanzapine (Zyprexa℗): suspected serious reactions. CMAJ . 2000; 163 85-86
185 Habersetzer F, Larrey D, Babany G. Clotiazepam-induced acute hepatitis. J Hepatol . 1989; 9 256-259
186 Andrade R J, Lucena M I, Aguilar J. Chronic liver injury related to use of bentazepam. Dig Dis Sci . 2000; 45 1400-1404
187 Anderson B N, Henrikson I R. Jaundice and eosinophilia associated with amitriptyline. J Clin Psychiatry . 1978; 39 730-731
188 Horst D A, Grace N D, LeCompte P M. Prolonged cholestasis and progressive hepatic fibrosis following imipramine therapy. Gastroenterology . 1980; 79 550-554
189 Cooper G L. The safety of fluoxetine-an update. Br J Psychiatry . 1988; 3 77-86
190 Cai Q, Benson M A, Talbot T J. Acute hepatitis due to fluoxetine therapy. Mayo Clin Proc . 1999; 74 692-694
191 Friedenberg F K, Rothstein K D. Hepatitis secondary to fluoxetine treatment (letter). Am J Psychiatry . 1996; 153 580
192 Capella D, Bruguera M, Figueras A, Laporte J. Fluoxetine-induced hepatitis: why is postmarketing surveillance needed?. Eur J Clin Pharmacol . 1999; 55 545-546
193 Johnston D E, Wheeler D E. Chronic hepatitis related to use of fluoxetine. Am J Gastroenterol . 1997; 92 1225-1226
194 Benbow S J, Gill G. Paroxetine and hepatotoxicity. BMJ . 1997; 314 1387
195 Helmchen C, Boerner R J, Meyendorf R, Hegerl U. Reversible hepatotoxicity of paroxetine in a patient with major depression. Pharmacopsychiatry . 1996; 29 223-226
196 Odeh M, Misselevech I, Boss J H, Oliven A. Severe hepatotoxicity with jaundice associated with paroxetine. Am J Gastroenterol . 2001; 96 2494-2496
197 Lucena M I, Andrade R J, Gomez-Outes A. Acute liver failure after treatment with nefazodone. Dig Dis Sci . 1999; 44 2577-2579
198 Aranda-Michel J, Koehler A, Bejarano P A. Nefazodone-induced liver failure: report of three cases. Ann Intern Med . 1999; 130 285-288
199 Schirren C A, Baretton G. Nefazodone-induced acute liver failure. Am J Gastroenterol . 2000; 95 1596-1597
200 Eloubeidi M A, Gaede J T, Swaim M W. Reversible nefazodone-induced liver failure. Dig Dis Sci . 2000; 45 1036-1038
201 Sheikh K H, Nies A S. Trazodone and intrahepatic cholestasis. Ann Intern Med . 1983; 99 572
202 Beck P L, Bridges R J, Demetrick D J. Chronic active hepatitis with trazodone therapy. Ann Intern Med . 1993; 118 791-792
203 Fernandes N F, Martin R R, Schenker S. Trazodone-induced hepatotoxicity: a case report with comments on drug-induced hepatotoxicity. Am J Gastroenterol . 2000; 95 532-535
204 Kim K Y, Hwang W, Narendran R. Acute liver damage possibly related to sertraline and venlafaxine ingestion. Ann Pharmacother . 1999; 33 381-382
205 Hull M, Jones R, Bendall M. Fatal hepatic necrosis associated with trazodone and neuroleptic drugs. BMJ . 1994; 309 378